Cogent Biosciences has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $225 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Cogent Biosciences is raising $225,000,000.00 in new funding. About Cogent Biosciences: Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
To learn more about Cogent Biosciences, visit http://www.cogentbio.com/
Contact:
Andrew Robbins, President and Chief Executive Officer
617-945-5576
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.